Amgen Inc. (AMGN) Balance Sheet

The dramatic reduction in leverage is driven by both debt reduction (from $64.0B to $57.3B) and a significant improvement in equity, which rose from $5.0B to $11.7B over the period. This suggests that retained earnings and improved profitability are rebuilding the equity base, though the absolute debt level remains high. The trend indicates a deliberate deleveraging path, but the pace is slow relative to the size of the debt, and the balance sheet remains strained.

Although Amgen has reduced total debt from its peak of $64.0B in Q1 2024, the absolute level remains substantial, and the debt-to-equity ratio, while improved, is still far above peers like Gilead (1.10) and Biogen (0.38). The high leverage appears to be a strategic choice to fund acquisitions like Horizon, but it exposes the company to interest rate risk and refinancing risk, especially if cash flows weaken. The debt load may limit capacity for further M&A or share repurchases, and investors should monitor the maturity schedule for potential refinancing needs.

Goodwill has remained stable at $18.7B, suggesting no impairments to date, but it represents a significant portion of total assets (about 20%). This implies that a substantial part of the company's value is tied to acquired businesses, which could be at risk if growth expectations are not met. PPE has grown from $6.0B to $8.5B, reflecting continued investment in manufacturing capacity, which aligns with the company's biomanufacturing moat. However, the asset mix is intangible-heavy, which may increase earnings volatility if impairments occur.

The improvement in equity is primarily due to retained earnings, as the accumulated deficit narrowed by $5.6B over the period. This suggests that Amgen is generating sufficient profits to offset historical losses, likely from the Horizon acquisition. However, the equity base remains thin relative to total assets, and the company continues to pay dividends, which may limit the speed of equity accumulation. The lack of significant share repurchases, as indicated by stable share counts, suggests that management is prioritizing debt reduction over returning capital beyond dividends.

Amgen's cash balance has increased from $9.7B to $14.0B, and the current ratio remains above 1.0, suggesting adequate short-term liquidity to cover obligations. The cash position provides a buffer against operational shocks and supports debt servicing, but it is modest relative to total debt of $57.3B. The improvement in liquidity is a positive sign, but the company still relies on ongoing cash flows to meet its obligations, and any disruption could strain liquidity.